Literature DB >> 3082318

A medium-term corneal preserving medium (K-Sol).

C W Yau, H E Kaufman.   

Abstract

A new corneal preserving solution, K-Sol, was prepared by combining TC 199, 100 mg/L of gentamicin sulfate, 0.025M HEPES buffer to a pH of 7.4, and various concentrations (2.0%; 2.25%; 2.5%) of chondroitin sulfate to a final osmolality of 310 mOsm. Rabbit corneas stored at 4 degrees C for 12 days in each solution, as well as fresh controls, were used for penetrating keratoplasty. Three weeks later, one graft in the 2.0% group was opacified; the rest were clear and showed minimal thickening. There were no significant differences between controls in terms of pachymetry and endothelial cell loss. This study supports the finding that K-Sol with 2.5% chondroitin sulfate is a simple, effective, medium-term preserving solution for donor tissue for penetrating keratoplasty in rabbits.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082318     DOI: 10.1001/archopht.1986.01050160154032

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  6 in total

1.  K-Sol corneal preservation at room temperature.

Authors:  K Tamaki; E D Varnell; H E Kaufman
Journal:  Br J Ophthalmol       Date:  1988-05       Impact factor: 4.638

Review 2.  Advances in corneal preservation.

Authors:  R L Lindstrom
Journal:  Trans Am Ophthalmol Soc       Date:  1990

3.  An analysis of corneal endothelial and graft survival in pseudophakic bullous keratopathy.

Authors:  A Sugar
Journal:  Trans Am Ophthalmol Soc       Date:  1989

4.  Hypothermic preservation of corneas in a hyperkalaemic solution (CPTES): II. Extended storage in the presence of chondroitin sulphate.

Authors:  M J Taylor; C J Hunt; P W Madden
Journal:  Br J Ophthalmol       Date:  1989-10       Impact factor: 4.638

5.  Endothelial cell damage in human and rabbit corneas stored in K-Sol without antioxidants.

Authors:  T S Reddy; E D Varnell; R W Beuerman; N G Bazan; H E Kaufman
Journal:  Br J Ophthalmol       Date:  1989-10       Impact factor: 4.638

6.  Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.

Authors:  Cheng-Wen Lin; Bryan Sherman; Lori A Moore; Carmen L Laethem; Da-Wen Lu; Padmanabhan P Pattabiraman; Ponugoti Vasantha Rao; Mitchell A deLong; Casey C Kopczynski
Journal:  J Ocul Pharmacol Ther       Date:  2017-06-13       Impact factor: 2.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.